Seoul [South Korea], December 26: ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced that ABL Bio will receive a USD 40 million upfront payment for the license, research and collaboration agreement for its Grabody platform, and a USD 15 million equity inv
Washington [US], September 2 (ANI): Researchers have published results that show encouraging therapeutic options for patients with blood cancer and multiple myeloma after first-line treatment with bispecific antibodies fails. Bispecific antibodies are a type of antibody that can bind to two